Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
NCT05652673
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Melanoma Stage IV
Melanoma Stage III
Immunotherapy
Toxicity, Drug
Interventions
DRUG:
nivolumab
Sponsor
Erasmus Medical Center